PE20070951A1 - Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva - Google Patents

Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva

Info

Publication number
PE20070951A1
PE20070951A1 PE2007000132A PE2007000132A PE20070951A1 PE 20070951 A1 PE20070951 A1 PE 20070951A1 PE 2007000132 A PE2007000132 A PE 2007000132A PE 2007000132 A PE2007000132 A PE 2007000132A PE 20070951 A1 PE20070951 A1 PE 20070951A1
Authority
PE
Peru
Prior art keywords
composition
concentration
active
active principles
aerosols
Prior art date
Application number
PE2007000132A
Other languages
English (en)
Inventor
Erhard Berkel
Hubert Hoelz
Friedrich Schmidt
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38266105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20070951(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20070951A1 publication Critical patent/PE20070951A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE A) DOS PRINCIPIOS ACTIVOS O MAS TAL COMO BECLOMETASONA, BUDESONIDA, FENOTEROL, FLUTICASONA, SALBUTAMOL, TERBUTALINA, BROMURO DE IPRATROPIO, ENTRE OTROS, DONDE UNO DE ELLOS ESTA PRESENTE EN FORMA DISUELTA Y EL OTRO PRINCIPIO ACTIVO EN FORMA DE PARTICULAS SUSPENDIDAS; B) UN TENSIOACTIVO TAL COMO MONOLAURATO DE POLIOXIETILEN-20-SORBITANO, TRIOLEATO DE POLIOXIETILENGLICEROL, ENTRE OTROS, QUE SE ENCUENTRA EN UNA CONCENTRACION DE 0,001 A 5% M/M DE LA COMPOSICION; C) UN CODISOLVENTE TAL COMO ETANOL QUE SE ENCUENTRA EN UNA CONCENTRACION DE 0,0001 A 50% M/M DE LA COMPOSICION; D) UN ESTABILIZANTE TAL COMO ACIDO CITRICO QUE SE ENCUENTRA EN UNA CONCENTRACION DE 0,0001 A 0,02% M/M DE LA COMPOSICION. DICHA COMPOSICION ES UN AEROSOL OPERADO CON GAS PROPELENTE CON UN HIDROCARBURO FLUORADO TAL COMO 1,1,2,2-TETRAFLUOROETANO O 1,1,1,2,3,3,3-HEPTAFLUOROPROPANO
PE2007000132A 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva PE20070951A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006006207 2006-02-09
DE102006053374A DE102006053374A1 (de) 2006-02-09 2006-11-10 Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz

Publications (1)

Publication Number Publication Date
PE20070951A1 true PE20070951A1 (es) 2007-09-24

Family

ID=38266105

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001533A PE20120023A1 (es) 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
PE2007000132A PE20070951A1 (es) 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011001533A PE20120023A1 (es) 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva

Country Status (19)

Country Link
US (1) US20070183982A1 (es)
EP (1) EP1988874A2 (es)
JP (1) JP2009526012A (es)
KR (1) KR20080098656A (es)
CN (1) CN102861339A (es)
AR (1) AR059350A1 (es)
AU (1) AU2007213819B2 (es)
BR (1) BRPI0707594A2 (es)
CA (1) CA2641883A1 (es)
DE (1) DE102006053374A1 (es)
EA (1) EA014776B1 (es)
EC (1) ECSP088653A (es)
IL (1) IL193274A0 (es)
NO (1) NO20083375L (es)
NZ (1) NZ571016A (es)
PE (2) PE20120023A1 (es)
TW (1) TW200800294A (es)
UY (1) UY30139A1 (es)
WO (1) WO2007090822A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ552869A (en) * 2004-07-02 2010-06-25 Boehringer Ingelheim Int Aerosol suspension formulations containing TG 227 ea as a propellant, an ipratropium or tiotropium salt and a small amount of free water to stabilise the composition
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
US9265910B2 (en) 2009-05-18 2016-02-23 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and nebulizer
CN102686260B (zh) 2009-11-25 2014-10-01 贝林格尔.英格海姆国际有限公司 喷雾器
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012087094A1 (es) * 2010-12-21 2012-06-28 Techsphere S.A. De C.V. Composición farmacéutica inhalable para el tratamiento del asma por administración vía aérea mediante un succionador de emulación de aerosol
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
EP3030298B1 (en) 2013-08-09 2017-10-11 Boehringer Ingelheim International GmbH Nebulizer
EP2835146B1 (en) 2013-08-09 2020-09-30 Boehringer Ingelheim International GmbH Nebulizer
RU2536253C1 (ru) * 2013-10-09 2014-12-20 Шолекс Девелопмент Гмбх Комбинированный аэрозольный препарат для лечения болезней органов дыхания
EP3139982B1 (en) 2014-05-07 2022-02-16 Boehringer Ingelheim International GmbH Nebulizer
KR102443737B1 (ko) 2014-05-07 2022-09-19 베링거 인겔하임 인터내셔날 게엠베하 컨테이너, 분무기 및 사용 방법
DK3139984T3 (da) 2014-05-07 2021-07-19 Boehringer Ingelheim Int Forstøver
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
EP3280393A1 (en) * 2015-04-10 2018-02-14 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN110876723A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的异丙托溴铵喷雾剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1230472A (es) * 1967-07-10 1971-05-05
DE3767615D1 (de) * 1986-03-10 1991-02-28 Kurt Burghart Pharmazeutikum sowie verfahren zu seiner herstellung.
WO1992022286A1 (en) * 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
US6932962B1 (en) * 1994-12-22 2005-08-23 Astrazeneca Ab Aerosol drug formulations containing hydrofluoroalkanes and alkyl saccharides
US6392962B1 (en) * 1995-05-18 2002-05-21 Rmp, Inc. Method of sleep time measurement
GB9626960D0 (en) * 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
DE69912781T2 (de) * 1998-06-18 2004-10-21 Boehringer Ingelheim Pharma Zwei oder mehrere wirkstoffe enthaltende pharmazeutische aerosolformulierungen
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
CA2496699C (en) * 2002-08-29 2012-07-17 Cipla Ltd. Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
AU2004224367B2 (en) * 2003-03-20 2009-10-08 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20050191246A1 (en) * 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
NZ552869A (en) * 2004-07-02 2010-06-25 Boehringer Ingelheim Int Aerosol suspension formulations containing TG 227 ea as a propellant, an ipratropium or tiotropium salt and a small amount of free water to stabilise the composition

Also Published As

Publication number Publication date
CA2641883A1 (en) 2007-08-16
US20070183982A1 (en) 2007-08-09
NZ571016A (en) 2012-01-12
WO2007090822A3 (de) 2007-11-08
JP2009526012A (ja) 2009-07-16
CN102861339A (zh) 2013-01-09
EA200801767A1 (ru) 2009-02-27
UY30139A1 (es) 2007-09-28
AU2007213819B2 (en) 2012-11-15
BRPI0707594A2 (pt) 2011-05-10
AU2007213819A1 (en) 2007-08-16
PE20120023A1 (es) 2012-02-13
EA014776B1 (ru) 2011-02-28
TW200800294A (en) 2008-01-01
EP1988874A2 (de) 2008-11-12
DE102006053374A1 (de) 2007-08-16
WO2007090822A2 (de) 2007-08-16
KR20080098656A (ko) 2008-11-11
ECSP088653A (es) 2008-10-31
IL193274A0 (en) 2009-08-03
NO20083375L (no) 2008-10-30
AR059350A1 (es) 2008-03-26

Similar Documents

Publication Publication Date Title
PE20070951A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
PE20161132A1 (es) Composicion combinada de bromuro de glicopirronio y formoterol en solucion estable presurizada para aerosol
BRPI0607574A2 (pt) composição farmacêutica aerossol
CL2012001705A1 (es) Composición farmacéutica que comprende a) bromuro de glicopirronio, b) formoterol o fumarato de formoterol y c) dipropionato de beclometasona, disueltos en hfa134a y etanol (entre 10-15 % p/p), hcl 1m entre 0,15-0,28µg/µl; frasco; combinación farmaceútica; método para rellenar el frasco; y su uso en asma y/o epoc
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
CL2012001668A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio disuelto en un propulsor de hidrofluoroalcano y 5 a 25% de etanol, que contiene de 0,005 y 1 µg/µl de acido clorhidrico 1m; metodo de relleno de un recipiente de aerosol con la composicion farmaceutica; uso en epoc, entre otros.
AR123674A2 (es) Composición farmacéutica en aerosol de formoterol y dipropionato de beclometasona
PE20091691A1 (es) Formulacion para inhalacion que comprende aclidinio
BRPI1006790B8 (pt) método para desenvolver uma composição farmacêutica líquida a ser aplicada na pele como uma espuma e composição adequada para uso tópico
PE20091852A1 (es) Formulacion farmaceutica que comprende un anticuerpo de ox40l
PE20141036A1 (es) Nueva dosificacion y formulacion
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
AR059844A1 (es) Nuevas composiciones topicas en forma de emulsion ac/ag que comprenden un glicol propenetrante
PE20020576A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos y corticoesteroides
GEP20227418B (en) Combination therapy for copd
AR089302A1 (es) Un medicamento inhalable
BR112015009595A2 (pt) massa fibrosa à base de alumina, processo para produção e uso da mesma
BR112015027017A2 (pt) composições farmacêuticas inaláveis e dispositivos inaladores que contêm as mesmas
JP2019528316A5 (es)
PE20240629A1 (es) Formulacion farmaceutica para inhalador presurizado de dosis medidas
AR099963A2 (es) Formulación farmaceutica en aerosol para inhaladores de dosis medida presurizados que comprenden un agente secuestrante, inhalador y método para llenar
AR085059A1 (es) Composicion resistente a la corrosion y farmaceuticamente estable para inhalador presurizado de dosis medida y metodo para generarla
NO20083759L (no) Doserings aerosoler for administrering av farmasoytiske preparater
JP2014527056A5 (es)
PE20221867A1 (es) Inhaladores de dosis medida presurizada que comprenden una formulacion farmaceutica amortiguada

Legal Events

Date Code Title Description
FC Refusal